U.S. FDA Approves Oraquick Advance(R) 12-Month Shelf Life Dating

Main Category: HIV / AIDS
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 29 Jan 2009 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:3 stars

3 (1 votes)


OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the United States Food and Drug Administration (FDA) has approved its request for 12-month shelf life from the date of manufacture for its OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test.

The FDA approval is based on enhancements made by OraSure to the manufacturing process and product packaging of its OraQuick ADVANCE® test, and represents a six-month increase in shelf life versus current product available on the market. The Company anticipates having the enhanced product available for delivery starting in March 2009.

"The quality and accuracy of our products is our highest priority and these enhancements to our OraQuick ADVANCE® product represents years of work to make what we believe is the best product available on the market even better," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "These enhancements will ensure that OraQuick ADVANCE® continues to deliver highly accurate results, consistently and in accordance with our FDA approved package insert claims."

OraQuick ADVANCE® is the first and only FDA-approved and CLIA-waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood or plasma specimens. As the market leader, OraQuick ADVANCE® is used extensively throughout the country in public health settings, hospitals, community-based organizations, and physician offices where HIV testing is conducted.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid testing solutions for drugs of abuse and for the detection of antibodies to HIV.

OraSure Technologies

Article adapted by Medical News Today from original press release.
Visit our hiv / aids section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
OraSure Technologies, Inc.. "U.S. FDA Approves Oraquick Advance(R) 12-Month Shelf Life Dating." Medical News Today. MediLexicon, Intl., 29 Jan. 2009. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/137131.php>

APA
OraSure Technologies, Inc.. (2009, January 29). "U.S. FDA Approves Oraquick Advance(R) 12-Month Shelf Life Dating." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/137131.php.

Please note: If no author information is provided, the source is cited instead.




HIV / AIDS

Most Popular Articles



Follow Our HIV News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our HIV / AIDS Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »